Event Calendar Test

The following resource is a repository for surveys conducted of our URMA members to gain insight into understanding organization’s demographics, communication teams, the kind of content that we produce and so much more. Click on a survey title below to view more information about the survey as well as the results.

2022 URMA Member Survey

ABOUT THE SURVEY

This year, we focused on 4 main topics:

  1. Better understanding the organization’s demographics, so we can better serve and expand our membership, identify and overcome our biases, and improve our own DEI efforts
  2. The kinds of teams that we are on, our backgrounds, and our salaries (perhaps to assist in future negotiation efforts!?)
  3. The kinds of content we produce and what we do with that content, and
  4. Magazines, especially our digital presence. This is meant to complement the previous survey, which heavily explored print magazines.

Special thanks to Edyta Zielinska, Chelsea Julian, and Joe McClain, who provided very useful feedback during the survey planning process.

Question may be sent to Gail L. McCormick

Download the 2022 URMA Member Survey

Oct
13

2nd Annual Schoenberg Lectureship in partnership with Science Sundays: “Shooting the messenger: ‘Antisense’ therapies for rare diseases”

2nd Annual Schoenberg Lectureship in partnership with Science Sundays: “Shooting the messenger: ‘Antisense’ therapies for rare diseases”

TIME: 3:00 pm—5:00 pm EST

FORMAT: In-Person at Fawcett Event Center
2400 Olentangy River Rd.
Columbus, OH 43210
United States

Ongoing basic research to understand how cells decode the information present in our genes has recently made it possible to develop new types of drugs. We will discuss one of the key steps in this genetic decoding, namely how messenger RNA (mRNA) undergoes splicing. Splicing edits each mRNA to remove non-coding segments, so that the information it carries can be used to make a protein. We will also discuss how mRNA splicing can be precisely manipulated with designer drugs called antisense oligonucleotides (ASOs), for example to correct defective splicing in the context of disease. One notable example we will discuss is an ASO drug that is being used to prevent or treat a deadly neurodegenerative disease. This event is free and open to the public.

REGISTER TODAY!